Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS

Inhibiting the androgen receptor (AR) pathway is an important clinical strategy in metastatic prostate cancer. Novel agents including abiraterone acetate and enzalutamide have been shown to prolong life in men with metastatic, castration-resistant prostate cancer (mCRPC). To evaluate the pharmacokin...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Pharm Biomed Anal
Asıl Yazarlar: Kim, Kyu-pyo, Parise, Robert A., Holleran, Julianne L., Lewis, Lionel D., Appleman, Leonard, van Erp, Nielka, Morris, Michael J., Beumer, Jan H.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2017
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5357460/
https://ncbi.nlm.nih.gov/pubmed/28219796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jpba.2017.02.018
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller